OnKure Therapeutics Other Non-Current Liabilities 2020-2024 | OKUR

OnKure Therapeutics other non-current liabilities from 2020 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.

OnKure Therapeutics Other Non-Current Liabilities 2020-2024 | OKUR

OnKure Therapeutics other non-current liabilities from 2020 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$88.1B
Takeda Pharmaceutical (TAK)$44.8B
Merck (MKGAF)$21.8B
Astellas Pharma (ALPMY)$20.6B
Sandoz Group AG (SDZNY)$18.4B
Summit Therapeutics (SMMT)$17B
United Therapeutics (UTHR)$16.5B
Shionogi (SGIOY)$12.2B
Neurocrine Biosciences (NBIX)$12B
Catalent (CTLT)$10.9B
Orion OYJ (ORINY)$7.4B
Jazz Pharmaceuticals (JAZZ)$7.1B
Ionis Pharmaceuticals (IONS)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.5B
Corcept Therapeutics (CORT)$4.9B
Crinetics Pharmaceuticals (CRNX)$4.7B
Madrigal Pharmaceuticals (MDGL)$4.7B
Dyne Therapeutics (DYN)$3.6B
PTC Therapeutics (PTCT)$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
Soleno Therapeutics (SLNO)$2.1B
Recursion Pharmaceuticals (RXRX)$2B
Harrow (HROW)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Ocular Therapeutix (OCUL)$1.8B
NewAmsterdam Pharma (NAMS)$1.7B
ARS Pharmaceuticals (SPRY)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B